论文部分内容阅读
目的:探讨晚期非小细胞肺癌(NSCLC)患者化疗获益后采用参一胶囊维持治疗的临床疗效。方法:选择2010年11月到2014年11月在我院经一线化疗后疗效评价无病情进展的120例晚期NSCLC患者,随机分为对照组(n=60)和实验组(n=60)。对照组仅接受定期随访观察,实验组采用参一胶囊维持治疗,比较两组患者治疗后的临床疗效、治疗前后免疫功能、生活质量的变化及不良反应的发生情况。结果:实验组患者的疾病控制率(DCR)明显高于对照组(P<0.05)。治疗后,两组患者各免疫功能检测指标均低于治疗前,且实验组明显大于对照组(P>0.05)。治疗后,实验组KPS评分提高率明显高于对照组(P<0.05)。整个维持治疗过程中无治疗相关性死亡。结论:晚期NSCLC患者在化疗后采用参一胶囊维持治疗,可显著提高患者免疫功能、改善生活质量,且安全性良好,疗效显著,值得在临床上推广应用。
Objective: To investigate the clinical effect of using Shen capsule in the treatment of advanced non-small cell lung cancer (NSCLC) after chemotherapy. Methods: A total of 120 patients with advanced non-small cell lung cancer (NSCLC) who had no disease progression after first-line chemotherapy in our hospital from November 2010 to November 2014 were randomly divided into control group (n = 60) and experimental group (n = 60). The control group received only regular follow-up observation. The experimental group was treated with Shenyi Capsule. The clinical efficacy, immune function and quality of life before and after treatment were compared between the two groups. The incidence of adverse reactions was compared. Results: The disease control rate (DCR) in the experimental group was significantly higher than that in the control group (P <0.05). After treatment, the indexes of immune function in both groups were lower than before treatment, and the experimental group was significantly larger than the control group (P> 0.05). After treatment, the experimental group KPS score was significantly higher than the control group (P <0.05). There was no treatment-related death throughout maintenance therapy. Conclusion: The treatment of Shen-capsule by advanced NSCLC patients after chemotherapy can significantly improve the immune function, improve the quality of life, and the safety is good, the curative effect is significant, which is worth popularizing and applying in clinic.